J Rheumatol 2021 May 1. Epub 2021 May 1.
M.N. Magrey, MD, Professor of Medicine, Case Western Reserve University School of Medicine, Director, Rheumatology Fellowship and Spondylarthritis Clinic, MetroHealth Medical Center, Cleveland, Ohio; P.J. Mease, MD, MACR, Director of Rheumatology Research, Swedish Medical Center/ Providence-St Joseph Health, Clinical Professor, University of Washington School of Medicine, Seattle, Washington, USA. MNM is a consultant for Novartis, AbbVie, UCB, Eli Lilly, and Pfizer; has clinical trials with AbbVie and UCB; and has no conflicts pertinent to this editorial. PJM receives research grants from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun, and UCB; is a consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sun, and UCB; and is on speakers bureaus for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Address correspondence to Dr. M.N. Magrey, 2500 MetroHealth Drive, Cleveland, OH 44109, USA. Email:
The conceptual paradigm of axial spondyloarthritis (axSpA) has evolved and now comprises an expanded spectrum that includes more females and patients with little or no radiographic changes in sacroiliitis or syndesmophyte formation in the spine. This broadened paradigm is often, but not always, characterized by an inflammatory magnetic resonance imaging (MRI) signature. Read More